Literature DB >> 7522494

Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.

J D Smith1, C B Bruce, A S Featherstone, R G Downing, B Biryahawaho, J C Clegg, J W Carswell, J D Oram.   

Abstract

The specificities of antibodies reacting with peptides encoded by V3 loop apical epitopes were determined for sera from 230 seropositive Ugandans, including asymptomatic persons and AIDS patients, sampled between 1986 and 1992. Most (71%) of the sera reacted with the peptide encoded by HIV-MN, 59% reacted with a peptide containing a consensus sequence for Ugandan variants of the HIV-1 global subtype A (referred to as the Uganda A consensus), 59% reacted with a peptide containing a consensus sequence for Ugandan variants of the global subtype D (the Uganda D consensus); 19% of the sera also reacted with peptides encoded by the divergent Ugandan variant U31. There was no obvious correlation between the specificities of antibody binding and the V3 loop sequence of the corresponding virus isolate or provirus. Competitive inhibition and antibody adsorption experiments indicated that the MN peptide, the Uganda A consensus peptide, the Uganda D consensus peptide, and the U31 peptide were recognized by different sets of antibodies. Eighteen percent of the sera from AIDS patients and 26% of the sera from asymptomatic persons were monospecific for one of the MN, Uganda A, or Uganda D peptides. Whereas all except one of the singly reactive AIDS sera were specific for MN, 39% of the singly reactive asymptomatic sera were specific for MN, 39% for the Uganda A peptide, and 21% for the Uganda D peptides. We conclude that analysis of the specificities of antibodies against the V3 loop epitopes in sera from asymptomatic persons could provide useful epidemiological data about the prevalence of viral subtypes within a population.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Africa; Africa South Of The Sahara; Antibodies; Antigen-antibody Reactions; Antigens; Biology; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Examinations And Diagnoses; Hiv; Hiv Infections; Hiv Serodiagnosis; Immunity; Immunologic Factors; Laboratory Examinations And Diagnoses; Measurement; Physiology; Prevalence; Proteins; Research Methodology; Uganda; Viral Diseases

Mesh:

Substances:

Year:  1994        PMID: 7522494     DOI: 10.1089/aid.1994.10.577

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

Authors:  J P Moore; F E McCutchan; S W Poon; J Mascola; J Liu; Y Cao; D D Ho
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

2.  A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.

Authors:  Rajesh Ringe; Deepak Sharma; Susan Zolla-Pazner; Sanjay Phogat; Arun Risbud; Madhuri Thakar; Ramesh Paranjape; Jayanta Bhattacharya
Journal:  Virology       Date:  2011-08-17       Impact factor: 3.616

3.  Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotyping.

Authors:  J C Plantier; S Le Pogam; F Poisson; L Buzelay; B Lejeune; F Barin
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Predominance of HIV-1 subtype A and D infections in Uganda.

Authors:  D J Hu; J Baggs; R G Downing; D Pieniazek; J Dorn; C Fridlund; B Biryahwaho; S D Sempala; M A Rayfield; T J Dondero; R Lal
Journal:  Emerg Infect Dis       Date:  2000 Nov-Dec       Impact factor: 6.883

5.  Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.

Authors:  Alisen Ayitewala; Fred Kyeyune; Pamela Ainembabazi; Eva Nabulime; Charles Drago Kato; Immaculate Nankya
Journal:  AIDS Res Ther       Date:  2020-01-31       Impact factor: 2.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.